Monday, February 16, 2026 2/16/2026

Translation Rewiring Underlines Drug Resistance to Lethal Targeted Ribosome Biogenesis Therapeutics in Cancer

Award Number: K99CA279786
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 02/01/2024
PERIOD OF PERFORMANCE END DATE: 01/31/2026

Group Awards By:

View Award Description

Translation Rewiring Underlines Drug Resistance to Lethal Targeted Ribosome Biogenesis Therapeutics in Cancer - Project Summary/Abstract Increased ribosome biogenesis is a hallmark of cancer and reflects the increased and pervasive protein synthetic needs of the cancer cells. Targeting this process by curbing the rate-limiting step, RNA polymerase I (Pol I) transcription, using specific inhibitors abrogating this activity, is a promising strategy for cancer therapy. BMH-21 is a first-in-class small molecule that inhibits Pol I transcription and large-scale cancer cell line screens demonstrated its potent efficacy across broad cancer lineages. However, a heterogeneous response was observed emphasizing the presence of mechanisms dampening the therapeutic response. Genome-wide positive selection CRISPR Cas9 knock-out screens were performed in human colorectal carcinoma cells to identify genes that cause resistance to the selective inhibition of Pol I. The screens identified all key positive regulators of the mTORC1 pathway accounting for the resistance. mTOR is a major driver of ribosome biogenesis and cellular translational programs and considered essential for cancer growth. The inactivation of mTOR as a resistance mechanism is counterintuitive, as this mechanism requires a reduced translational state by the cancer cells and inactivation of two key pathways enabling protein synthesis. These unexpected findings led to the hypothesis that cancer cells evade severe ribosome biogenesis stress by switching off mTOR-dependent translational pathways. This premise stipulates that bypass mechanisms have evolved to facilitate translation of essential proteins for survival and growth when cancer cells face obstacles in protein translation. This concept will be tested using pharmacological and genetic approaches that block mTOR. The goal of the project is to gain knowledge on the mechanisms that enable unabated ribosome translation in cancer cells. The following aims will be implemented to achieve this goal: Aim 1. Identify genes driving resistance to Pol I and translation inhibitor, Aim 2. Investigate the translational activity maintained under translation stress in cancer cells and Aim 3. Identify the regulators of ribosome activity that support survival by translation stress. By executing these aims we will gain knowledge how cancer cells survive severe translational stress and the mechanisms of this escape. These studies will identify critical processes and proteins required for survival and how their translation is maintained with limited ribosome numbers. These findings have implications in therapeutic strategies that target ribosome biogenesis, protein synthesis and translation and the approaches are designed to use this knowledge to develop new combination strategies to overcome these resistance mechanisms.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $109,705 )
2025	2025	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Cancer Research Manpower	000	2	1/15/2025	NON-COMPETING CONTINUATION	$109,705
														Subtotal = $109,705

Issue Date FY: 2024 ( Subtotal = $109,489 )
2024	2024	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Cancer Research Manpower	000	1	1/19/2024	NEW	$109,489
														Subtotal = $109,489

Grand Total All Awards = $219,194

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Translation Rewiring Underlines Drug Resistance to Lethal Targeted Ribosome Biogenesis Therapeutics in Cancer

Award Number: K99CA279786

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 02/01/2024

PERIOD OF PERFORMANCE END DATE: 01/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer